General policy should be documented and published. Policy documentation may specify, for example:
• Situations in which data on bioequivalence are required;
• Whether and under what circumstances evaluation reports prepared by another DRA will be accepted;
• Which fixed-dose combinations are considered rational, safe and effective.
The advantage of such “in principle” policies is that decisions on individual applications become easier and less time-consuming.